Approaching datasets for big pharma
J&J moves FcRn towards a big new therapy area, while Bristol, Merck, Astrazeneca and Daiichi Sankyo await important oncology catalysts.
UCB leads the stale scale
Several big groups’ portfolios are ageing, and regulatory action risks blocking their renewal.
Hidradenitis suppurativa promise sends Moonlake soaring
Strong mid-stage data seem to show sonelokimab, a Merck KGaA cast-off, beating bigger rivals.
Novartis takes the helicopter view on Chinook
After Calliditas and Travere secure US approvals Novartis doubles down on a rare kidney disease, but what will the FTC say?
Mulling biopharma’s Minority Report moment
Amgen might yet prevail in its attempt to buy Horizon, but the FTC shockwaves will still be felt.
The waxing and waning of the speedy approval
As the FDA cools on the accelerated pathway, could biopharma’s annual approval count take a hit?